{"id":"injection-of-placebo-of-apomorphine","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Orthostatic hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Apomorphine works by binding to dopamine receptors in the brain, which can help to alleviate symptoms of Parkinson's disease. This is achieved by mimicking the action of dopamine, a neurotransmitter that is often deficient in individuals with Parkinson's disease. By increasing dopamine activity, apomorphine can help to improve motor function and reduce symptoms such as tremors and rigidity.","oneSentence":"Apomorphine is a dopamine agonist that mimics the action of dopamine in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:18.115Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"},{"name":"Drug-induced extrapyramidal reactions"}]},"trialDetails":[{"nctId":"NCT06954428","phase":"PHASE1","title":"Clinical Trial of Intranasal Delivery of NT-301","status":"COMPLETED","sponsor":"Nano PharmaSolutions Australia","startDate":"2025-06-20","conditions":"Tolerability of NT-301 Nasal Spray, Pharmacokinetics of NT-301 Nasal Spray, Safety of NT-301 Nasal Spray","enrollment":49},{"nctId":"NCT01432821","phase":"NA","title":"Blinking and Yawning in Epilepsy: The Role of Dopamine","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2011-09","conditions":"Idiopathic Generalized Epilepsy","enrollment":31},{"nctId":"NCT04879134","phase":"PHASE2, PHASE3","title":"Apomorphine Effects on Pain in Parkinson's Disease","status":"UNKNOWN","sponsor":"University of Calgary","startDate":"2022-02-28","conditions":"Parkinson Disease","enrollment":40},{"nctId":"NCT01058291","phase":"PHASE3","title":"Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2010-01","conditions":"Parkinson's Disease","enrollment":31},{"nctId":"NCT01504178","phase":"PHASE3","title":"Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2011-05","conditions":"Parkinson's Disease","enrollment":28},{"nctId":"NCT00200512","phase":"PHASE2, PHASE3","title":"Continued Efficacy of Apomorphine After Previous Exposure of at Least Three Months","status":"COMPLETED","sponsor":"Mylan Bertek Pharmaceuticals","startDate":"1999-09","conditions":"Parkinson Disease","enrollment":16},{"nctId":"NCT00200525","phase":"PHASE3","title":"Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease","status":"COMPLETED","sponsor":"Mylan Bertek Pharmaceuticals","startDate":"2001-07","conditions":"Parkinson Disease","enrollment":60},{"nctId":"NCT00145171","phase":"PHASE3","title":"A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients.","status":"COMPLETED","sponsor":"Mylan Bertek Pharmaceuticals","startDate":"2001-02","conditions":"Parkinson Disease","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":58,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"injection of placebo of apomorphine","genericName":"injection of placebo of apomorphine","companyName":"University Hospital, Toulouse","companyId":"university-hospital-toulouse","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Apomorphine is a dopamine agonist that mimics the action of dopamine in the brain. Used for Parkinson's disease, Drug-induced extrapyramidal reactions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}